PlumX Metrics
Embed PlumX Metrics

Vision loss in glioblastoma: Disease mimicking presumed therapeutic toxicity

Neuro-Oncology Practice, ISSN: 2054-2585, Vol: 5, Issue: 4, Page: 223-226
2018
  • 2
    Citations
  • 0
    Usage
  • 5
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Glioblastoma is the most common and lethal form of primary brain cancer. In the recurrent setting, bevacizumab is a common choice for salvage therapy. Loss of vision in patients initially treated with radiation at the time of diagnosis and later treated with bevacizumab at time of recurrence has been reported, and presumed to be a treatment-related optic neuropathy. Strikingly, only 1 case report described a postmortem biopsy to rule out tumor involvement of the optic tracts. We report the first case of recurrent glioblastoma infiltrating the prechiasmatic and chiasmatic optic nerve, which at the time of vision loss was presumed to be secondary to bevacizumab. It is noteworthy that the MRI findings in the previously reported bevacizumab/radiation-induced optic neuropathy cases (without pathology follow-up) are comparable to our patient.

Bibliographic Details

Nguyen, HuyTram N; Vo, Kevin B H; Howard, Steven; Salamat, M Shahriar; Rowely, Howard; Robins, H Ian

Oxford University Press (OUP)

Medicine; Neuroscience

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know